Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL versus FILSPARI.
CANDESARTAN CILEXETIL vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively and competitively binds to the angiotensin II type 1 (AT1) receptor, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This results in decreased peripheral resistance and blood pressure.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Oral, 8 mg once daily initially, titrate to 16-32 mg once daily as tolerated; maximum 32 mg/day.
200 mg orally once daily, with or without food.
None Documented
None Documented
Clinical Note
moderateCandesartan cilexetil + Torasemide
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Torasemide."
Clinical Note
moderateCandesartan cilexetil + Etacrynic acid
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Etacrynic acid."
Clinical Note
moderateCandesartan cilexetil + Furosemide
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Furosemide."
Clinical Note
moderateThe terminal elimination half-life is approximately 9 hours. In clinical practice, this supports once-daily dosing, with steady state achieved within 3–4 days.
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Candesartan is eliminated primarily via the kidneys (approximately 60% of recovered dose) and the feces (approximately 40%) following biliary excretion. Less than 1% is excreted unchanged in urine.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category D/X
Category C
ARB
Endothelin Receptor Antagonist / ARB
Candesartan cilexetil + Bumetanide
"The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Bumetanide."